<DOC>
	<DOC>NCT01412801</DOC>
	<brief_summary>The study compared the magnitude of the antibody response and safety of a GBS Trivalent Vaccine in HIV positive and HIV negative pregnant women and their offspring. In addition the study investigated the maternal to fetal transfer of antibodies induced by the investigational vaccine.</brief_summary>
	<brief_title>Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pregnant women 1840 years of age between 2435 weeks gestation Women who were HIVneg or HIVpos with WHO stage I or II disease and with CD4+ counts &gt; 50 cells/µL Women who had CD4+ count ≤ 50 cells/µL Women who were HIVpos with WHO stage III or IV disease, history of severe allergic reactions after previous vaccinations</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Group B streptococcus</keyword>
	<keyword>GBS</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Prevention of group B streptococcus infection</keyword>
</DOC>